Oxford, UK, 20 April 2024
Dr Danuta Jeziorska steps down as CEO of Nucleome Therapeutics
Oxford, UK, 20 April 2024 – Dr Danuta Jeziorska, the Chief Executive Officer and Scientific Founder of Nucleome, steps down by mutual agrement, after successfully building the Company from inception into a leading biotechnology company decoding the dark matter of the human genome for translational medicine.
Dr Jeziorska led the spin-out of Nucleome as the first female scientific founder from the Weatherall Institute of Molecular Medicine at Oxford University in 2019. Since then, she has led the Company development of a highly productive innovative platform that has enabled the discovery of a portfolio of first-in-class targets through dark genome’s genetics, with the most advanced candidate on a path to enter drug discovery stage in the near future. She also played a crucial role in advancing Nucleome’s strategic initiatives, successfully leading two funding rounds, including an oversubscribed Series A fundraise, bringing in $55 million and a top-tier syndicate of investors. As CEO, she has built a strong company culture, with a seasoned executive team and assembled a diverse, multidisciplinary team of ~40. Her direction and expertise have been instrumental in driving the Company’s commitment to developing first-in-class precision medicines for diseases with high unmet need and the management team will work to continue the execution of Nucleome’s strategy and ensure a smooth transition.
Dr Danuta Jeziorska said: “It has been a privilege to lead and work with such an incredible team at Nucleome. We have achieved so much together, and I could not be more proud. I founded Nucleome through passion and ambition to bring curative treatments to patients; I am incredibly proud that we have now discovered a portfolio of targets and are moving towards drug discovery to fulfil this vision. The business is in a very strong position and set for future success. I am grateful for the support of the investors and the team.”
Dr Russell Greig, Chair of the Board of Directors at Nucleome, added: “Danuta’s vision, combined with strong ambition, strategic foresight and steadfast guidance have led the company to the strong position it enjoys today. On behalf of the Board and the Executive team, I want to thank Danuta for her unwavering dedication and leadership in building Nucleome. We are confident to continue to carry out this vision and we remain committed to building on the strong foundation she has built.”
– Ends –
About Nucleome Therapeutics
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the Company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit www.nucleome.com.
For more information, please contact:
Nucleome Therapeutics
Dr Russell Greig, Chair of the Board
ICR Consilium
Sukaina Virji / Evi Useh / Jack Bissett